ADLYXIN Drug Profile

Summary for Tradename: ADLYXIN

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for ADLYXIN

See drug prices for ADLYXIN

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ADLYXIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ADLYXIN Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ADLYXIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2030-05-05	Patent claims search
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2039-02-26	Patent claims search
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2035-03-18	Patent claims search
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2031-01-26	Patent claims search

Market Dynamics and Financial Trajectory for Adlyxin

Introduction to Adlyxin

Adlyxin, also known as lixisenatide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes. It is administered via subcutaneous injection and has been marketed by Sanofi since its approval in 2016[4].

Market Reception

Adlyxin entered the market with significant expectations as a fixed-dose combination therapy with insulin glargine (Soliqua) in a once-daily regimen. Despite launching before Novo Nordisk’s Xultophy, Adlyxin generated underwhelming sales since its launch. However, recent data showing its efficacy compared to premixed insulins has led Sanofi executives to express optimism about its future prospects[4].

Sales Performance

Adlyxin has shown steady sales performance, although it has not reached the peak sales forecasts. In 2021, the full-year sales were $126 million in the U.S. and $214 million globally[4]. Analysts have forecasted peak sales of $288 million by 2026, indicating a gradual growth trajectory[4].

Competitive Landscape

The GLP-1 receptor agonist market is highly competitive, with several key players including Eli Lilly, Novo Nordisk, and Sanofi. Novo Nordisk’s semaglutide (Ozempic/Wegovy) has been a standout success, generating over $3 billion in global sales in 2020 and expected to exceed $12 billion by 2027. This competition has driven innovation and pricing strategies in the market[4].

Financial Performance

Sanofi’s financial reports indicate that Adlyxin contributes to the company’s overall revenue from diabetes treatments. In 2023, Adlyxin was part of the Soliqua product line, which generated significant revenue. However, detailed financial data for Adlyxin specifically is not provided in the available reports. The company’s overall financial performance is influenced by various factors including royalty payments and milestone revenues from partnerships[3].

Future Prospects

Despite initial underperformance, Adlyxin remains a crucial component in Sanofi’s diabetes treatment portfolio. The company continues to focus on improving glycemic control and expanding its product offerings. Recent data suggesting its efficacy over premixed insulins indicates potential for increased market share and future growth[4].

Key Takeaways

1. Market Entry: Adlyxin entered the market with high expectations but faced initial underperformance.
2. Sales Performance: Steady sales with $126 million in U.S. sales and $214 million globally in 2021.
3. Competitive Landscape: Highly competitive market with Novo Nordisk’s semaglutide being a standout success.
4. Financial Performance: Contributes to Sanofi’s overall revenue from diabetes treatments.
5. Future Prospects: Potential for increased market share and future growth based on recent efficacy data.

FAQs

1. What is Adlyxin?

   • Adlyxin is a GLP-1 receptor agonist used in the treatment of type 2 diabetes.

2. Who markets Adlyxin?

   • Adlyxin is marketed by Sanofi.

3. What are the sales figures for Adlyxin?

   • In 2021, Adlyxin generated $126 million in U.S. sales and $214 million globally[4].

4. How does Adlyxin compete in the market?

   • The market is highly competitive, with Novo Nordisk’s semaglutide being a significant competitor[4].

5. What are the future prospects for Adlyxin?

   • Recent data indicating its efficacy over premixed insulins suggests potential for increased market share and future growth[4].

---

Sources Cited

1. Grand View Research - GLP-1 Receptor Agonist Market Size & Share Report, 2030
2. Biospace - Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
3. Zealand Pharma - Annual Report 2017
4. Diabetes Post-Approval Insights - Sales and Market Reception of Adlyxin
5. Zealand Pharma - Annual Report 2023